Emerging echinocandin-resistant Candida albicans and glabrata in Switzerland.

Authors :: Coste, A. T.
Kritikos, A.
Li, J.
Khanna, N.
Goldenberger, D.
Garzoni, C.
Zehnder, C.
Boggian, K.
Neofytos, D.
Riat, A.
Bachmann, D.
Sanglard, D.
Lamoth, F.
The Fungal Infection Network of Switzerland (FUNGINOS)
Source :: Infection; Oct2020, Vol. 48 Issue 5, p761-766, 6p, 2 Charts
Publication Year :: 2020
Abstract: Echinocandins represent the first-line therapy of candidemia. Echinocandin resistance among Candida spp. is mainly due to acquired FKS mutations. In this study, we report the emergence of FKS-mutant Candida albicans/glabrata in Switzerland and provide the microbiological and clinical characteristics of 9 candidemic episodes. All patients were previously exposed to echinocandins (median 26 days; range 15–77). Five patients received initial echinocandin therapy with persistent candidemia in 4 of them. Overall mortality was 33%. [ABSTRACT FROM AUTHOR]